Program Overview

The SITC Immuno-oncology Drug Development Summit will educate the IO community on the regulatory paths for the next wave of IO therapeutics, including:

  • Cellular therapies (CAR-T, TCR-T, gamma delta T cell, other immune cells)
  • CD3 TCE and Bi-specifics
  • mRNA vaccine and other vaccines
  • Oncolytic virus
  • Next gen ICI (TIGIT, LAG3, bi-specifics, small molecule)
  • Innovative cytokines

Organizers

Amy McKee, MD

Amy McKee, MD
Parexel

Pedro Romero, MD

Pedro Romero, MD
Novigenix

Luisa Salter-Cid, MD

Luisa Salter-Cid, MD
Flagship Pioneering

Alexandra Snyder, MD

Alexandra Snyder, MD
Generate Biomedicines

Dr. Jon Wigginton_Bright Peak.png

Jon Wigginton, MD
Bright Peak Therapeutics 

Get the Latest Updates

We are currently finalizing the registration for this program. If you are interested, please add your name to the form and we will email you when the program details are confirmed.

Target Audience

Physicians and scientists in academia, industry (including emerging biotech companies), investors and regulatory agencies who have an interest in the strategic, preclinical, clinical and regulatory aspects of efficient IO drug development. This program will also support those who are beginning careers in IO drug development.

Learning Objectives

  1. Describe key informational resources and implement best practices regarding the development of immuno-oncology therapeutics
  2. Develop relationships between regulatory agencies, industry members, and academic investigators to develop effective strategies for the development of immuno-oncology therapeutics
  3. Integrate scientific and regulatory objectives to develop preclinical and clinical strategies that drive efficient development of immuno-oncology therapeutics
  4. Design effective clinical trials specific to immuno-oncology therapeutics that reflect regulatory expectations and requirements